RE: Expected Monetary Impact of Oncotype DX Score-Concordant Systemic Breast Cancer Therapy Based on the TAILORx Trial.

Paolo Giorgi Rossi, Eugenio Paci

Research output: Contribution to journalArticlepeer-review

Original languageEnglish
JournalJournal of the National Cancer Institute
DOIs
Publication statusE-pub ahead of print - Jun 19 2019

Cite this